Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market – Industry Trends and Forecast to 2027

  • Healthcare
  • Published Report
  • Oct 2020
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 214
  • No of Figures: 52

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market, By Cancer Type (Lung, Breast, Colorectal, Prostrate, Stomach, Cervical, Leukemia and Others), Product & Service (Kits, Software & Services and Instruments), Technologies (Panels/Targeted Sequencing & Resequencing, Whole Exome Sequencing, Whole Genome Sequencing, RNA Sequencing and Other Sequencing Technologies), Workflow (NGS Sequencing, NGS Data Analysis and NGS Pre-Sequencing), Application (Screening, Companion Diagnostics and Others), End User (Pathology Labs, Hospitals, Oncology Centers and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Japan, Hong Kong, India, South Korea, Australia, Singapore, Thailand, Taiwan, New Zealand, Malaysia, Indonesia, Vietnam, Macao, Philippines and Rest of Asia-Pacific) Industry Trends & Forecast to 2027

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic MarketMarket Analysis and Insights : Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market

Next generation sequencing (NGS) in cancer diagnostic market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2020 to 2027 and is expected to reach USD 1,510.64 million by 2027 from USD 321.86 million in 2019.

Rising incidence of cancer in the Asia-pacific region and increase in the adoption of this technique over single-gene testing among more are the major drivers which propelled the demand of the market in the forecast period.

Next generation sequencing or NGS is also known as high-throughput sequencing. It is an exceptional technology which arranges massive DNA strands through huge parallelization. The breakthrough reduces the need for segment cloning that is used in Sanger genome sequencing. The main benefits that NGS provides over Sanger's sequencing methodology are fast procedures, precise performance, and organizational ease even from small sample data. With the development of new technologies and cancer cure treatment, the next-generation sequencing market in clinical oncology has huge potential in the coming years.

Major factors driving the growth of Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market are government initiatives taken in the developed and developing countries of Asia-Pacific region to increase the number of research projects for oncology and preventative diagnosis, rising incidence of cancer in Asia-Pacific region and rising requirement for cancer diagnostic and the factor which hampers the growth of the next generation sequencing (NGS) in cancer diagnostic market includes high installation and maintenance of the cost associated with the NGS equipment’s and lack of experienced professionals.

The next generation sequencing (NGS) in cancer diagnostic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic MarketAsia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Scope and Market Size

Next generation sequencing (NGS) in cancer diagnostic market is segmented on the basis of cancer type, product & service, technologies, workflow, application, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of cancer type, the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market is segmented into lung, breast, colorectal, prostrate, stomach, cervical, leukemia and others. In 2020, lung cancer segment is dominating the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market because of the increasingly common incidence of slow-growing cancer and the most prevalent form of cancer. As a result, healthcare providers are focusing towards research, diagnosis & treatment for the same.
  • On the basis of product & service, the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market is segmented into kits, software & services and instruments. In 2020, kits segment is dominating the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market as the most important component of consumables required for conducting next generation sequencing procedures. The kits also hold a significant share of per procedure cost.
  • On the basis of technologies, the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market is segmented into panels/targeted sequencing & resequencing, whole exome sequencing, whole genome sequencing, RNA sequencing and other sequencing technologies. In 2020, the panels/targeted sequencing & resequencing segment is dominating the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market as it plays a crucial role in cancer diagnosis. Targeted sequencing is able to point out causative mutations within the genome by isolating and sequencing genomic regions of interest from a sample library.
  • On the basis of workflow, the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market is segmented into NGS sequencing, NGS data analysis and NGS pre-sequencing. In 2020, the NGS sequencing is dominating in the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market as the most resource intensive stage in the next generation sequencing approaches for cancer diagnosis. At this stage, the procedure is conducted to obtain genomic data. The data collected in this step provides crucial information for cancer diagnosis.
  • On the basis of application, the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market is segmented into screening, companion diagnostics and others. The screening segment is further segmented into sporadic cancer and inherited cancer. In 2020, screening is dominating in the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market as NGS is primary being used in the area of liquid biopsy and utilized to sequence tumor DNA enabling a non-invasive process and real-time monitoring of disease development. The ability of NGS to provide a molecular profile of cancer makes it useful in screening and hence the adoption is increasing among oncologists. Screening through NGS can be used across all stages of cancer diagnosis.
  • On the basis of end user, the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market is segmented into pathology labs, hospitals, oncology centers and others. In 2020, pathology labs is dominating in the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market as next generation sequencing for cancer diagnosis is being conducted by laboratories to test for tumor mutations & other disorders. Moreover, the preference by healthcare providers for the process being conducted by pathology labs instead of conducting NGS in-house is also augmenting the market.
  • On the basis of distribution channel, the Asia-pacific next generation sequencing (NGS) in cancer diagnostic market is segmented into direct tender and retail sales. In 2020, direct tender is dominating in the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market as the products are specialized and vendors offer high level of services by expects in the company.

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic MarketNext Generation Sequencing (NGS) in Cancer Diagnostic Market Country Level Analysis

The next generation sequencing (NGS) in cancer diagnostic market is analysed and market size information is provided by cancer type, product & service, technologies, workflow, application, end user and distribution channel.

The countries covered in the next generation sequencing (NGS) in cancer diagnostic market report are the South Korea, Japan, India, Australia, Singapore, Taiwan, Hong Kong, Malaysia, Indonesia, New Zealand, Thailand, Vietnam, Macao, Philippines and Rest of Asia-Pacific.

The Asia-Pacific region is expected to grow with the most promising growth rate in the forecast period of 2020 to 2027 because of increasing awareness regarding early diagnosis. Japan is dominating Asia-Pacific market due to rising incidence of cancer in this region and increasing government initiatives towards the R&D for cancer diagnostics using NGS. Australia is the second most growing country in the Asia-Pacific region because of the availability of variety of products launched by the key market players in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Funding in Research & Testing Labs is Creating New Opportunities for Players in the Next Generation Sequencing (NGS) in Cancer Diagnostic Market

Next generation sequencing (NGS) in cancer diagnostic market also provides you with detailed market analysis for every country growth in particular industry with next generation sequencing (NGS) in cancer diagnostic sales, impact of advancement in the next generation sequencing (NGS) in cancer diagnostic and changes in regulatory scenarios with their support for the next generation sequencing (NGS) in cancer diagnostic market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Next Generation Sequencing (NGS) in Cancer Diagnostic Market Share Analysis

Next generation sequencing (NGS) in cancer diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to next generation sequencing (NGS) in cancer diagnostic market.

The major players covered in the report are Agilent Technologies, Inc., Twist Bioscience, Millennium Science Pty Ltd, Dow Biomedica Co., Spinco Biotech Pvt Ltd, Quantabio, Swift Biosciences Inc., ArcherDX, Inc., Premas Life Sciences and TOMY DIGITAL BIOLOGY CO., LTD, among other domestic and Asia-Pacific players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the next generation sequencing (NGS) in cancer diagnostic market.

For instance,

  • In March 2020, Agilent Technologies, Inc. launched three new microarrays to address the requirements of prenatal and postnatal research in cytogenetic laboratories. These new product launched by the company increases its NGS product portfolio leading to increased demand for its products in future.
  • In November 2019, TOMY DIGITAL BIOLOGY CO.,LTD. underwent a partnership with WASAI Technology Inc. in order to distribute the genome sequencing solutions of the WASAI Technology Inc. in Japan region. This partnership done by the company has increased its demand in the Asia-Pacific region leading to increased sales and revenue of its product in the market.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the next generation sequencing (NGS) in cancer diagnostic market which also provides the benefit for organisation to improve their offering for Next generation sequencing (NGS) in cancer diagnostic.

Customization Available: Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES 

TABLE 1 NGS COST PER SAMPLE

TABLE 2 COMPARISON OF COST OF VARIOUS NGS PLATFORMS

TABLE 3 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 4 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 5 ASIA-PACIFIC KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 6 ASIA-PACIFIC SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 7 ASIA-PACIFIC SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 8 ASIA-PACIFIC SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 9 ASIA-PACIFIC ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 10 ASIA-PACIFIC ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 11 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 12 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 13 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 14 ASIA-PACIFIC SCREENING IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 15 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 16 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 17 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

TABLE 18 JAPAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 19 JAPAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 20 JAPAN KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 21 JAPAN SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 22 JAPAN SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 23 JAPAN SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 24 JAPAN ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 25 JAPAN ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 26 JAPAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 27 JAPAN IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 28 JAPAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 29 ASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 30 JAPAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 31 JAPAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 32 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 33 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 34 AUSTRALIA KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 35 AUSTRALIA SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 36 AUSTRALIA SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 37 AUSTRALIA SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 38 AUSTRALIA ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 39 AUSTRALIA ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 40 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 41 AUSTRALIA IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 42 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 43 ASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 44 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 45 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 46 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 47 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 48 SOUTH KOREA KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 49 SOUTH KOREA SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 50 SOUTH KOREA SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 51 SOUTH KOREA SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 52 SOUTH KOREA ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 53 SOUTH KOREA ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 54 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 55 SOUTH KOREA IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 56 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 57 ASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 58 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 59 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 60 INDIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 61 INDIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 62 INDIA KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 63 INDIA SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 64 INDIA SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 65 INDIA SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 66 INDIA ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 67 INDIA ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 68 INDIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 69 INDIA IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 70 INDIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 71 ASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 72 INDIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 73 INDIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 74 SINGAPORE NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 75 SINGAPORE NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 76 SINGAPORE KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 77 SINGAPORE SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 78 SINGAPORE SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 79 SINGAPORE SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 80 SINGAPORE ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 81 SINGAPORE ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 82 SINGAPORE NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 83 SINGAPORE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 84 SINGAPORE NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 85 ASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 86 SINGAPORE NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 87 SINGAPORE NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 88 TAIWAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 89 TAIWAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 90 TAIWAN KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 91 TAIWAN SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 92 TAIWAN SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 93 TAIWAN SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 94 TAIWAN ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 95 TAIWAN ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 96 TAIWAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 97 TAIWAN IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 98 TAIWAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 99 ASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 100 TAIWAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 101 TAIWAN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 102 HONG KONG NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 103 HONG KONG NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 104 HONG KONG KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 105 HONG KONG SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 106 HONG KONG SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 107 HONG KONG SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 108 HONG KONG ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 109 HONG KONG ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 110 HONG KONG NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 111 HONG KONG IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 112 HONG KONG NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 113 ASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 114 HONG KONG NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 115 HONG KONG NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 116 MALAYSIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 117 MALAYSIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 118 MALAYSIA KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 119 MALAYSIA SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 120 MALAYSIA SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 121 MALAYSIA SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 122 MALAYSIA ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 123 MALAYSIA ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 124 MALAYSIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 125 MALAYSIA IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 126 MALAYSIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 127 MALAYASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 128 MALAYSIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 129 MALAYSIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 130 THAILAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 131 THAILAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 132 THAILAND KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 133 THAILAND SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 134 THAILAND SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 135 THAILAND SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 136 THAILAND ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 137 THAILAND ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 138 THAILAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 139 THAILAND IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 140 THAILAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 141 ASIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 142 THAILAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 143 THAILAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 144 NEW ZEALAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 145 NEW ZEALAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 146 NEW ZEALAND KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 147 NEW ZEALAND SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 148 NEW ZEALAND SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 149 NEW ZEALAND SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 150 NEW ZEALAND ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 151 NEW ZEALAND ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 152 NEW ZEALAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 153 NEW ZEALAND IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 154 NEW ZEALAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 155 NEW ZEALAND SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 156 NEW ZEALAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 157 NEW ZEALAND NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 158 INDONESIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 159 INDONESIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 160 INDONESIA KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 161 INDONESIA SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 162 INDONESIA SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 163 INDONESIA SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 164 INDONESIA ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 165 INDONESIA ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 166 INDONESIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 167 INDONESIA IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 168 INDONESIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 169 INDONESIA SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 170 INDONESIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 171 INDONESIA NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 172 VIETNAM NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 173 VIETNAM NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 174 VIETNAM KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 175 VIETNAM SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 176 VIETNAM SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 177 VIETNAM SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 178 VIETNAM ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 179 VIETNAM ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 180 VIETNAM NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 181 VIETNAM IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 182 VIETNAM NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 183 VIETNAM SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 184 VIETNAM NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 185 VIETNAM NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 186 MACAO NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 187 MACAO NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 188 MACAO KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 189 MACAO SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 190 MACAO SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 191 MACAO SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 192 MACAO ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 193 MACAO ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 194 MACAO NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 195 MACAO IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 196 MACAO NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 197 MACAO SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 198 MACAO NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 199 MACAO NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 200 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

TABLE 201 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 202 PHILIPPINES KITS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 203 PHILIPPINES SOFTWARE & SERVICES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 204 PHILIPPINES SEQUENCING DATA ANALYSIS SOFTWARE IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 205 PHILIPPINES SECONDARY DATA ANALYSIS IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 206 PHILIPPINES ANNOTATION TOOLS (PRODUCTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 207 PHILIPPINES ANNOTATION TOOLS (VARIANTS) IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)

TABLE 208 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)

TABLE 209 PHILIPPINES IN NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY WORKFLOW, 2018-2027 (USD MILLION)

TABLE 210 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 211 PHILIPPINES SCREENING IN PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 212 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 213 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 214 REST OF ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) IN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions